New York, New York--(Newsfile Corp. - May 18, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ: REGN) concerning potential violations of the federal securities laws.

In March, the Senior Vice President of Investor Relations, Ryan Crowe, told investors management was "hopeful" for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS" and an "opportunity to have a statistically significant, clinically meaningful benefit on OS."

A little more than two months later, on May 16, 2026, Regeneron disclosed that fianlimab + Libtayo did not meet the trial's primary endpoint against Keytruda. The upbeat language on potential outcomes offered on March 10, 2026 failed to stress the risk of the trial failure. The stock fell sharply on the revelation.

If you suffered a loss on your Regeneron Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297842

Source: Levi & Korsinsky, LLP